Sponsored By:

9 Biotechnology Stocks to Buy Now

DRTX, RGLS, ARIA, OHRP, NBIX, ARRY, CLDX, BSTC, INSM improve in weekly rankings

   

This week, nine biotechnology stocks are improving their overall rating on Portfolio Grader. Each of these rates an “A” (“strong buy”) or “B” overall (“buy”).

This week, Durata Therapeutics, Inc. (DRTX) is showing significant improvement as the company’s rating hops from a C (“hold”) to a B (“buy”). In Portfolio Grader’s specific subcategory of Earnings Momentum, DRTX also gets an A. Shares of DRTX have increased 26.9% over the past month, better than the 1.3% decrease the Nasdaq has seen over the same period of time. For more information, get Portfolio Grader’s complete analysis of DRTX stock.

The rating of Regulus Therapeutics Inc. (RGLS) moves up this week, rising from a C to a B. Regulus Therapeutics focuses on the discovery and development of drugs that target microRNAs to treat various diseases in the United States. For more information, get Portfolio Grader’s complete analysis of RGLS stock.

ARIAD Pharmaceuticals, Inc. (ARIA) shows solid improvement this week. The company’s rating rises from a C to a B. ARIAD Pharmaceuticals is an oncology company that focuses on the discovery, development, and commercialization of medicines for cancer patients. For more information, get Portfolio Grader’s complete analysis of ARIA stock.

This week, Ohr Pharmaceutical, Inc. (OHRP) is making solid headway. The company’s rating improves to an A (“strong buy”) from last week’s B (“buy”) rating. For more information, get Portfolio Grader’s complete analysis of OHRP stock.

This week, Neurocrine Biosciences, Inc.’s (NBIX) ratings are up from a C last week to a B. Neurocrine Biosciences is focused on the discovery and development of therapeutics for neuropsychiatric, neuroinflammatory, and neurodegenerative diseases and disorders. For more information, get Portfolio Grader’s complete analysis of NBIX stock.

Array BioPharma (ARRY) is seeing ratings go up from a C last week to a B this week. Array BioPharma is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer, inflammatory and metabolic diseases. The stock finished at $5.32 per share, after five days of consecutive gains. For more information, get Portfolio Grader’s complete analysis of ARRY stock.

This is a strong week for Celldex Therapeutics, Inc. (CLDX). The company’s rating climbs to A from the previous week’s B. Celldex Therapeutics is engaged in the discovery, development and commercialization of products that harness the human immune system to prevent and treat disease. After seven consecutive days of gains, the stock price has reached $24.15. For more information, get Portfolio Grader’s complete analysis of CLDX stock.

BioSpecifics Technologies’ (BSTC) ratings are looking better this week, moving up to an A from last week’s B. BioSpecifics Technologies is a biopharmaceutical company that has been involved in the development of injectable collagenase for multiple indications. For more information, get Portfolio Grader’s complete analysis of BSTC stock.

Insmed Incorporated (INSM) boosts its rating from a C to a B this week. Insmed develops and commercializes drugs that treat metabolic diseases, endocrine disorders and oncology. Wall Street seems to agree with the upgrade and has propelled the stock up 5.1% over the past month. For more information, get Portfolio Grader’s complete analysis of INSM stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, http://investorplace.com/2013/11/9-biotechnology-stocks-to-buy-now-drtx-rgls-aria/.

©2014 InvestorPlace Media, LLC

Comments are currently unavailable. Please check back soon.